PPARγ inhibits HMGB1 expression through upregulation of miR-142-3p in vitro and in vivo

Cellular Signalling

Volumn 28, Issue 3, 2016, Pages 158-164

  Yuan, Zhiqiang ^a   Luo, Gaoxing ^a   Li, Xiaolu ^a   Chen, Jing ^a   Wu, Jun ^a   Peng, Yizhi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HMGB1; Inflammation; MiR 142 3p; PPAR

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; MICRORNA; MICRORNA 142 3P; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3' UNTRANSLATED REGION; ANTISENSE OLIGONUCLEOTIDE; CHROMAN DERIVATIVE; INTERLEUKIN 6; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENE CONTROL; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RAT; SEPSIS; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MONONUCLEAR CELL; MOUSE; PATHOLOGY; RNA INTERFERENCE; TRANSCRIPTION INITIATION;

3' UNTRANSLATED REGIONS; ANIMALS; CELLS, CULTURED; CHROMANS; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PPAR GAMMA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SEPSIS; THIAZOLIDINEDIONES; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84952648584     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2015.12.013     Document Type: Article

References (34)

1. Ramanan S., Kooshki M., Zhao W., Hsu F.C., Robbins M.E. PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic. Biol. Med. 2008, 45:1695-1704.
2. Kim H.J., Ham S.A., Kim S.U., Hwang J.Y., Kim J.H., Chang K.C., Yabe-Nishimura C., Kim J.H., Seo H.G. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta. Circ. Res. 2008, 102:193-200.
3. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7:48-52.
4. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
5. Bell C.W., Jiang W., Reich C.F., Pisetsky D.S. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 2006, 291:C1318-C1325.
6. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5:331-342.
7. Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., Giazzon M., Dumitriu I.E., Muller S., Iannacone M., Traversari C., Bianchi M.E., Manfredi A.A. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004, 5:825-830.
8. Harris H.E., Andersson U., Pisetsky D.S. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 2012, 8:195-202.
9. Bae J.S. Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch. Pharm. Res. 2012, 35:1511-1523.
10. Schickel R., Boyerinas B., Park S.M., Peter M.E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27:5959-5974.
11. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
12. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
13. O'Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10:111-122.
14. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12481-12486.
15. Sun X., Icli B., Wara A.K., Belkin N., He S., Kobzik L., Hunninghake G.M., Vera M.P., Registry M., Blackwell T.S., Baron R.M., Feinberg M.W. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J. Clin. Invest. 2012, 122:1973-1990.
16. Merline R., Moreth K., Beckmann J., Nastase M.V., Zeng-Brouwers J., Tralhao J.G., Lemarchand P., Pfeilschifter J., Schaefer R.M., Iozzo R.V., Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 2011, 4:ra75.
17. Sun Y., Varambally S., Maher C.A., Cao Q., Chockley P., Toubai T., Malter C., Nieves E., Tawara I., Wang Y., Ward P.A., Chinnaiyan A., Reddy P. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood 2011, 117:6172-6183.
18. Kanaan Z., Barnett R., Gardner S., Keskey B., Druen D., Billeter A., Cheadle W.G. Differential microRNA (miRNA) expression could explain microbial tolerance in a novel chronic peritonitis model. Innate Immun. 2013, 19:203-212.
19. Wang H., Vishnubhakat J.M., Bloom O., Zhang M., Ombrellino M., Sama A., Tracey K.J. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392.
20. Rendon-Mitchell B., Ochani M., Li J., Han J., Wang H., Yang H., Susarla S., Czura C., Mitchell R.A., Chen G., Sama A.E., Tracey K.J., Wang H. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 2003, 170:3890-3897.
21. Wang H., Ward M.F., Sama A.E. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009, 32:348-357.
22. Wang H., Yang H., Czura C.J., Sama A.E., Tracey K.J. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 2001, 164:1768-1773.
23. Kang R., Chen R., Zhang Q., Hou W., Wu S., Cao L., Huang J., Yu Y., Fan X.G., Yan Z., Sun X., Wang H., Wang Q., Tsung A., Billiar T.R., Zeh H.J., Lotze M.T., Tang D. HMGB1 in health and disease. Mol. Aspects Med. 2014, 40:1-116.
24. Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 2006, 17:321-327.
25. Szeles L., Torocsik D., Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim. Biophys. Acta 2007, 1771:1014-1030.
26. Gao M., Hu Z., Zheng Y., Zeng Y., Shen X., Zhong D., He F. Peroxisome proliferator-activated receptor gamma agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor kappaB and activator protein 1. Shock 2011, 36:228-234.
27. Hwang J.S., Lee W.J., Kang E.S., Ham S.A., Yoo T., Paek K.S., Lim D.S., Do J.T., Seo H.G. Ligand-activated peroxisome proliferator-activated receptor-delta and -gamma inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1. Cell Death Dis. 2014, 5.
28. Ramkissoon S.H., Mainwaring L.A., Ogasawara Y., Keyvanfar K., McCoy J.P., Sloand E.M., Kajigaya S., Young N.S. Hematopoietic-specific microRNA expression in human cells. Leuk. Res. 2006, 30:643-647.
29. Wang X.S., Gong J.N., Yu J., Wang F., Zhang X.H., Yin X.L., Tan Z.Q., Luo Z.M., Yang G.H., Shen C., Zhang J.W. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012, 119:4992-5004.
30. Lv M., Zhang X., Jia H., Li D., Zhang B., Zhang H., Hong M., Jiang T., Jiang Q., Lu J., Huang X., Huang B. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways. Leukemia 2012, 26:769-777.
31. Lei Z., Xu G., Wang L., Yang H., Liu X., Zhao J., Zhang H.T. MiR-142-3p represses TGF-beta-induced growth inhibition through repression of TGFbetaR1 in non-small cell lung cancer. FASEB J. 2014, 28:2696-2704.
32. MacKenzie T.N., Mujumdar N., Banerjee S., Sangwan V., Sarver A., Vickers S., Subramanian S., Saluja A.K. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol. Cancer Ther. 2013, 12:1266-1275.
33. Xu G., Wang J., Jia Y., Shen F., Han W., Kang Y. MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1. Cell. Physiol. Biochem. 2014, 33:1329-1339.
34. Shen W.W., Zeng Z., Zhu W.X., Fu G.H. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J. Mol. Med. Berl. 2013, 91:989-1000.